Skip to Content
Uncategorized

New UCSF Chancellor a Boost for Personalized Medicine?

Former Genentech president Susan Desmond-Hellmann is nominated to be the next UCSF chancellor.

When Roche bought Genentech last month, speculation was rife about where the newly enriched leadership of this biotech behemoth would end up. For president of product development Susan Desmond-Hellmann, it didn’t take long to settle the issue.

Last Friday, Mark Yudof, president of the University of California, announced that Desmond-Hellmann is his nominee for the chancellor of UC San Francisco–subject to approval by the UC Board of Regents. Her arrival could mean a substantial boost for personalized medicine–the tailoring of treatments and diagnostic tests according to an individual patient’s genes and physiology. She oversaw the development of Herceptin, the Genentech blockbuster to treat breast cancer that only works for patients who overexpress a gene called HER2. She also oversaw the development of the blockbusters Rituxin and Avastin.

Unfortunately, other examples of truly personalized medicine have been scarce in the drug industry, despite an explosion of research data produced by molecular biologists in recent years. Most of this data, however, has not been translated into either new drugs or diagnostics. Many reasons are given, including the complexity of the science and a research infrastructure that still values discovery more than the development and application of those discoveries.

Efforts are under way at the National Institutes of Health and at some universities to develop new and better methods to shift basic research in genetics, proteomics, and other fields into useful products and protocols, but no national leader has emerged to spearhead the effort.

Desmond-Hellmann has not yet revealed her plans or focus should she be approved as chancellor of UCSF, but she is uniquely poised to perhaps take on this role as a bridge between research and development.

Hopefully, she will keep the two in proper balance, remembering her first career as a full-time oncologist who joined pharma out of frustration at being able to do so little for her patients.

Deep Dive

Uncategorized

Five poems about the mind

DREAM VENDING MACHINE I feed it coins and watch the spring coil back,the clunk of a vacuum-packed, foil-wrappeddream dropping into the tray. It dispenses all kinds of dreams—bad dreams, good dreams,short nightmares to stave off worse ones, recurring dreams with a teacake marshmallow center.Hardboiled caramel dreams to tuck in your cheek,a bag of orange dreams…

Work reinvented: Tech will drive the office evolution

As organizations navigate a new world of hybrid work, tech innovation will be crucial for employee connection and collaboration.

lucid dreaming concept
lucid dreaming concept

I taught myself to lucid dream. You can too.

We still don’t know much about the experience of being aware that you’re dreaming—but a few researchers think it could help us find out more about how the brain works.

panpsychism concept
panpsychism concept

Is everything in the world a little bit conscious?

The idea that consciousness is widespread is attractive to many for intellectual and, perhaps, also emotional
reasons. But can it be tested? Surprisingly, perhaps it can.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.